BioCentury | Feb 22, 2020
Management Tracks

Everest names new CEO; plus Merck, Gilead, Turning Point, Adaptimmune, AskBio and more

...of translational gene therapy at the rare disease research unit of Pfizer Inc. (NYSE:PFE). The H3 Biomedicine Inc....
...diagnose and treat patients with cancer or hereditary disorders. BioCentury Staff Gilead Sciences Inc. Adaptimmune Therapeutics plc Asklepios BioPharmaceutical Inc. H3 Biomedicine Inc. OptiNose...
BioCentury | Nov 12, 2019
Company News

Skyhawk’s $80M Celgene deal expands remit to autoimmune

...December to develop splicing modifiers for cancer with Eisai Co. Ltd. (Tokyo:4523) and its subsidiary H3 Biomedicine Inc....
BioCentury | Nov 2, 2019
Company News

Management tracks: Genmab, Kintai, Aerie, Oasmia, Sangamo, Ovid, Checkmate, Third Pole, Actimed, IMV, Entasis, Rafael, Evaxion and Arvelle

...down to pursue other opportunities. Schindler was VP, clinical development and executive medical director at H3 Biomedicine Inc....
BioCentury | Jan 23, 2019
Distillery Therapeutics

Cancer

...of MCL1-dependent NSCLC, the SF3B1 modulator decreased tumor volume compared with vehicle. Next steps by H3 Biomedicine Inc....
...investigating the therapeutic window for SF3B1-mediated splicing modulation/Bcl-XL inhibitor combination in animal models of NSCLC. H3 Biomedicine...
...published online Jan. 11, 2019 doi:10.1038/s41467-018-08150-5 CONTACT: Ping Zhu, H3 Biomedicine Inc., Cambridge, Mass. email: ping_zhu@h3biomedicine.com Claire Quang H3 Biomedicine Inc. B...
BioCentury | Dec 21, 2018
Company News

BMS, H3 Biomedicine evaluate RNA splicing technology

...Bristol-Myers Squibb Co. (NYSE:BMY) and Eisai Co. Ltd. (Tokyo:4523), along with its subsidiary H3 Biomedicine, Inc. (Cambridge...
...and sales milestones as well as royalties. H3 and BMS declined to disclose financial terms. H3 Biomedicine Inc....
...New York, N.Y. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Business: Cancer Shannon Lehnbeuter Bristol-Myers Squibb Co. Eisai Co. Ltd. H3 Biomedicine Inc....
BioCentury | Jun 13, 2018
Company News

Management tracks: Salk Institute, Galectin

...CMO. She was director of drug development, oncology at Johnson & Johnson (NYSE:JNJ). Cancer company H3 Biomedicine Inc....
BioCentury | Mar 8, 2018
Emerging Company Profile

Splice time

...patent applications covering its platform, composition of matter and method of use for its molecules. H3 Biomedicine Inc....
...NASDAQ:BIIB), Cambridge, Mass. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Expansion Therapeutics Inc., San Diego, Calif. H3 Biomedicine Inc....
BioCentury | Feb 28, 2018
Distillery Therapeutics

Cancer

...in SF3B1 or SRSF2, H3B-8800 decreased tumor size compared with no treatment. Ongoing work by H3 Biomedicine Inc....
...published online Feb. 19, 2018 doi:10.1038/nm.4493 CONTACT: Silvia Buonamici, H3 Biomedicine Inc., Cambridge, Mass. email: silvia_buonamici@h3biomedicine.com Sandi Wong H3B-8800 H3 Biomedicine Inc. Serine/arginine-rich...
BioCentury | Feb 20, 2018
Preclinical News

New compound kills tumor cells with spliceosome mutations

...In a Nature Medicine study , researchers at H3 Biomedicine Inc. (Cambridge, Mass.) described development and preclinical proof-of-efficacy...
...with vehicle. This difference was not observed in leukemic mice with normal splice factor genes. H3 Biomedicine...
...to treat myelodysplastic syndromes, AML and CML. Initial data are expected this year. Sandi Wong H3B-8800 Eisai Co. Ltd. H3 Biomedicine Inc. Splicing...
BioCentury | Feb 9, 2018
Emerging Company Profile

Fast boat to China

...I for HCC: BLU-554 from Blueprint Medicines Corp., INCB62079 from Incyte Corp. and H3B-6527 from H3 Biomedicine Inc....
...Philadelphia, Pa. Blueprint Medicines Corp. (NASDAQ:BPMC), Cambridge, Mass. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan H3 Biomedicine Inc....
...Chengdu, China Incyte Corp. (NASDAQ:INCY), Wilmington, Del. Virginia Li, Staff Writer Abbisko Therapeutics Blueprint Medicines Corp. Daiichi Sankyo Co. Ltd. H3 Biomedicine Inc. Incyte...
Items per page:
1 - 10 of 30
BioCentury | Feb 22, 2020
Management Tracks

Everest names new CEO; plus Merck, Gilead, Turning Point, Adaptimmune, AskBio and more

...of translational gene therapy at the rare disease research unit of Pfizer Inc. (NYSE:PFE). The H3 Biomedicine Inc....
...diagnose and treat patients with cancer or hereditary disorders. BioCentury Staff Gilead Sciences Inc. Adaptimmune Therapeutics plc Asklepios BioPharmaceutical Inc. H3 Biomedicine Inc. OptiNose...
BioCentury | Nov 12, 2019
Company News

Skyhawk’s $80M Celgene deal expands remit to autoimmune

...December to develop splicing modifiers for cancer with Eisai Co. Ltd. (Tokyo:4523) and its subsidiary H3 Biomedicine Inc....
BioCentury | Nov 2, 2019
Company News

Management tracks: Genmab, Kintai, Aerie, Oasmia, Sangamo, Ovid, Checkmate, Third Pole, Actimed, IMV, Entasis, Rafael, Evaxion and Arvelle

...down to pursue other opportunities. Schindler was VP, clinical development and executive medical director at H3 Biomedicine Inc....
BioCentury | Jan 23, 2019
Distillery Therapeutics

Cancer

...of MCL1-dependent NSCLC, the SF3B1 modulator decreased tumor volume compared with vehicle. Next steps by H3 Biomedicine Inc....
...investigating the therapeutic window for SF3B1-mediated splicing modulation/Bcl-XL inhibitor combination in animal models of NSCLC. H3 Biomedicine...
...published online Jan. 11, 2019 doi:10.1038/s41467-018-08150-5 CONTACT: Ping Zhu, H3 Biomedicine Inc., Cambridge, Mass. email: ping_zhu@h3biomedicine.com Claire Quang H3 Biomedicine Inc. B...
BioCentury | Dec 21, 2018
Company News

BMS, H3 Biomedicine evaluate RNA splicing technology

...Bristol-Myers Squibb Co. (NYSE:BMY) and Eisai Co. Ltd. (Tokyo:4523), along with its subsidiary H3 Biomedicine, Inc. (Cambridge...
...and sales milestones as well as royalties. H3 and BMS declined to disclose financial terms. H3 Biomedicine Inc....
...New York, N.Y. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Business: Cancer Shannon Lehnbeuter Bristol-Myers Squibb Co. Eisai Co. Ltd. H3 Biomedicine Inc....
BioCentury | Jun 13, 2018
Company News

Management tracks: Salk Institute, Galectin

...CMO. She was director of drug development, oncology at Johnson & Johnson (NYSE:JNJ). Cancer company H3 Biomedicine Inc....
BioCentury | Mar 8, 2018
Emerging Company Profile

Splice time

...patent applications covering its platform, composition of matter and method of use for its molecules. H3 Biomedicine Inc....
...NASDAQ:BIIB), Cambridge, Mass. Eisai Co. Ltd. (Tokyo:4523), Tokyo, Japan Expansion Therapeutics Inc., San Diego, Calif. H3 Biomedicine Inc....
BioCentury | Feb 28, 2018
Distillery Therapeutics

Cancer

...in SF3B1 or SRSF2, H3B-8800 decreased tumor size compared with no treatment. Ongoing work by H3 Biomedicine Inc....
...published online Feb. 19, 2018 doi:10.1038/nm.4493 CONTACT: Silvia Buonamici, H3 Biomedicine Inc., Cambridge, Mass. email: silvia_buonamici@h3biomedicine.com Sandi Wong H3B-8800 H3 Biomedicine Inc. Serine/arginine-rich...
BioCentury | Feb 20, 2018
Preclinical News

New compound kills tumor cells with spliceosome mutations

...In a Nature Medicine study , researchers at H3 Biomedicine Inc. (Cambridge, Mass.) described development and preclinical proof-of-efficacy...
...with vehicle. This difference was not observed in leukemic mice with normal splice factor genes. H3 Biomedicine...
...to treat myelodysplastic syndromes, AML and CML. Initial data are expected this year. Sandi Wong H3B-8800 Eisai Co. Ltd. H3 Biomedicine Inc. Splicing...
BioCentury | Feb 9, 2018
Emerging Company Profile

Fast boat to China

...I for HCC: BLU-554 from Blueprint Medicines Corp., INCB62079 from Incyte Corp. and H3B-6527 from H3 Biomedicine Inc....
...Philadelphia, Pa. Blueprint Medicines Corp. (NASDAQ:BPMC), Cambridge, Mass. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan H3 Biomedicine Inc....
...Chengdu, China Incyte Corp. (NASDAQ:INCY), Wilmington, Del. Virginia Li, Staff Writer Abbisko Therapeutics Blueprint Medicines Corp. Daiichi Sankyo Co. Ltd. H3 Biomedicine Inc. Incyte...
Items per page:
1 - 10 of 30